Skip to main content

Table 1 The clinical trials of MSCs-EVs

From: Extracellular vesicles derived from different sources of mesenchymal stem cells: therapeutic effects and translational potential

Sources

Diseases

Intervention

N. Pats

Follow up

State

Location

Number/Ref.

BM-MSCs

Bronchopulmo-nary Dysplasia

Bone marrow mesenchymal stem cell-derived extracellular vesicles

18

40 weeks

Recruiting

Boston Children’s Hospital Boston, Massachusetts, United States Brigham and Women’s Hospital Boston, Massachusetts, United States (and 3 more…)

NCT03857841

BM-MSCs

Coronavirus

5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5)

30

3.5 months

Not yet recruiting

Ruijin Hospital, shanghai, China

NCT04276987

UC-MSCs

Chronic kidney disease

Umbilical cord MSC-EVs (100 μg/kg/dose)

20

1 year

Concluded

Sahel Teaching Hospital Sahel, Cairo, Egypt

[109]

UC-MSCs

Macular degeneration

Cord tissue MSC-EVs injected directly around macular hole

44

24 weeks

Recruiting

Tianjin Medical University Hospital Tianjin, China

NCT03437759

UC-MSCs

Dry Eye

Umbilical mesenchymal stem cells derived Exosomes

27

12 weeks

Recruiting

Zhongshan Ophthalmic Center Guangzhou, Guangdong, China

NCT04213248

UC-MSCs

Diabetes mellitus Type 1

Two doses of MSC-EVs

20

3 months

Unknown

Sahel Teaching Hospital Sahel, Cairo, Egypt

NCT02138331

AD-MSCs

Osteoarthritis

Secretome from adipose-derived mesenchymal stromal cells

24

3 years

Not yet recruiting

/

NCT04223622